(firstQuint)Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC).

 Docetaxel and vinorelbine are well known active agents in the treatment of NSCLC.

 The standard treatment of elderly patients with advanced NSCLC is monotherapy with a third generation agent.

 The role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation.

.

 Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)@highlight

This trial will compare the efficacy of docetaxel versus vinorelbine as first-line treatment in elderly patients with advanced NSCLC.

